The in vitro studies revealed that NPS 2143 was effective in rectifying the gain-of-function of the mutant Gln723 CaSR, and we therefore pursued studies to determine whether ip injection of the calcilytic compound NPS 2143 could improve the hypocalcemia associated with Nuf mice. The gene discussed is CASR; the disease is Hypocalcemia.